By a News Reporter-Staff News Editor at Clinical Trials Week Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell ... Pharmacy Choice, 1 day ago
MIRATI THERAPEUTICS : Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma - 4 Traders, 6 days ago
Mirati's Mocetinostat For Lymphoma Designated As Orphan Drug - Bioresearch Online, 1 week ago
More from: Reuters UK, Stock Nod...and 61 other sources
2 images for "mirati"
Mirati Therapeutics (NASDAQ: MRTX ): Q2 EPS of -$0.82 misses by $0.13 . Press Release PostSeeking Alpha, 2 weeks ago Mirati Therapeutics (MRTX) Releases Quarterly Earnings, Misses Estimates By $0.13 EPS American Banking News, 2 weeks ago
09:18 ET | About: Mirati Therapeutics, Inc. (MRTX) Mirati Therapeutics (NASDAQ:MRTX) Q2 results: Revenues: $0; Operating Loss: ($10.1M) (-46.4%); Net Loss: ($11.0M) (-37.5%); Loss Per Share: ($0.82) (-2.5%); Quick Assets: $47.4M (-23.7%). No ...Seeking Alpha, 2 weeks ago
Mirati Therapeutics Inc. entered into a triple net lease with ARE-SD Region No. 20 LLC for 18,000 square feet of office and laboratory space at 9393 Towne Centre Drive in San Diego, California. The office space will serve as new corporate ...CoStar Group, 1 month ago
Tenants Include: Foundation Medicine, Health Partners, Intralinks, JKG Group, Mast Therapeutics, Mirati Therapeutics, Nationwide Mutual, Relypsa, San Jose Mercury News and Vineyard Vines Nationwide Mutual Planning New 500,000-SF Campus In a ...CoStar Group, 1 month ago
(MarketLine via COMTEX News Network) -- Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported that net loss for the second quarter ended June 30, 2014 was $11.04 million, or $0.82 loss per share, compared to a net loss ...PredictWallStreet, 1 day ago
Filing Date 2014-08-08 Accepted 2014-08-08 16:01:50 Documents 3 Period of Report 2014-08-08 Filing Date Changed 2014-08-08 Items Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial ...SEC Filings, 2 weeks ago
Mirati Therapeutics (NASDAQ:MRTX) opened at 18.30 on Friday. Mirati Therapeutics has a 1-year low of $7.00 and a 1-year high of $25.97. The stock's 50-day moving average is $20.28 and its 200-day moving average is $19.79. The company's market cap is ...American Banking News, 1 month ago
Investment analysts at Brean Capital began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX) In other Mirati Therapeutics news, major shareholder Orbimed Advisors Llc sold 107,332 shares of Mirati Therapeutics stock on the open market in a ...American Banking News, 1 month ago
Shares of Mirati Therapeutics (NASDAQ:MRTX) were the recipient of a significant decline in short interest in the month of June. As of June 13th, there was short interest totalling 393,398 shares, a decline of 28.6% from the May 30th total of 550,920 ...American Banking News, 1 month ago
on your WebpageAdd Widget >Get your members hooked!